A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)
Venue: American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA
Abstract #: 6037
Authors: J Chen, Q Ji, J Cao, D Ji, C Bai, Y Lin, B Pan, G Sun, J Li, C Qi, Y Hua
Session: Head and Neck Cancer
Date & Time: Monday, June 5, 2017, 1:15 PM CDT
Location: Hall A